Asthma diagnosis and treatmentSalmeterol response is not affected by β2-adrenergic receptor genotype in subjects with persistent asthma
Section snippets
Subjects
Data from 2 identical studies, with results published in 2001 and 2002, in which DNA was collected were used for these analyses.19, 20 The replicate trials were designed to evaluate the efficacy and safety of fluticasone propionate/salmeterol (FSC), 100/50 μg Diskus (GlaxoSmithKline, Research Triangle Park, NC), in adolescent and adult subjects whose asthma was inadequately controlled with SABAs alone. Subjects were eligible for inclusion if they were 15 years of age or older and had a history
Baseline distributions
Genetic samples were available for 183 (43%) FSC recipients from the 2 identical studies. The distribution of the BUP-Cys/Arg, Arg16Gly, Gln27Glu, and Thr164Ile genotypes were all found to be in HWE. ADRB2 haplotype frequencies from unphased genotypes were estimated, and haplotype pairs were assigned to white individuals. Haplotype frequencies were not estimated in the other ethnic groups because of the small sample size.
There were no significant differences in baseline demographic, clinical,
Discussion
The results of the current study do not indicate a differential effect of ADRB2 polymorphisms on response to FSC therapy in subjects with asthma in this study. Prior studies suggest that the therapeutic responses to regularly scheduled therapy with short-acting bronchodilators vary as a result of genetic polymorphisms involving a variation at the 16th amino acid position of the β2-AR. A recent report by Wechsler et al16 analyzed data from the Salmeterol or Corticosteroids (SOCS) and Salmeterol
References (36)
- et al.
Family-based association analysis of β2-adrenergic receptor polymorphisms in the childhood asthma management program
J Allergy Clin Immunol
(2003) Airway smooth muscle: an immunomodulatory cell
J Allergy Clin Immunol
(2002)- et al.
Association of the Glu 27 β2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects
Lancet
(1995) Update on current concepts of the molecular basis of β2-adrenergic receptor signaling
J Allergy Clin Immunol
(2002)- et al.
A polymorphism of the human beta2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor
J Biol Chem
(1993) - et al.
Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomized, placebo-controlled cross-over trial
Lancet
(2004) - et al.
Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma
Ann Allergy Asthma Immunol
(2002) - et al.
α2A/α2C-adrenergic receptor third loop chimera show that agonist interaction with receptor subtype backbone establishes G protein-coupled receptor kinase phosphorylation
J Biol Chem
(2000) - et al.
Long-acting inhaled β2-agonists in asthma therapy
Chest
(1998) - et al.
Retrospective review of studies shows that subjects receiving salmeterol plus and ICS have fewer serious asthma exacerbations versus subjects on and ICS alone, regardless of ethnic origin
J Allergy Clin Immunol
(2004)
Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs
J Allergy Clin Immunol
Two-year retrospective economic evaluation of three dual-controller therapies used in the treatment of asthma
Chest
Complex promoter and coding region beta2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness
Proc Natl Acad Sci U S A
cDNA for the human β2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor
Proc Natl Acad Sci U S A
Mutations in the gene encoding for the β2-adrenergic receptor in normal and asthmatic subjects
Am J Respir Cell Mol Biol
Influence of β2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle
Am J Respir Cell Mol Biol
The effect of polymorphisms of the β2-adrenergic receptor on the response to regular use of albuterol in asthma
Am J Respir Crit Care Med
Asthma exacerbations during long term beta agonist use: influence of β2 adrenoceptor polymorphism
Thorax
Cited by (0)
Disclosure of potential conflict of interest: E. R. Bleecker has received grant support from Altana, AstraZeneca, Boehringer-Ingelheim, Centocor, Genentech, GlaxoSmithKline, and Novartis; has consultant arrangements with Aerovance, Altana, AstraZeneca, Centocor, Critical Therapeutics, Genentech, GlaxoSmithKline, and Novartis; and is on the speakers' bureau for AstraZeneca, GlaxoSmithKline, Genentech, and Merck. M. Klotsman and S. W. Yancey are both employed by and own stock in GlaxoSmithKline. W. H. Anderson, P. M. Dorinsky, L. A. Baitinger, and L. D. Edwards all are employed by GlaxoSmithKline.